Eupraxia Pharmaceuticals to Present RESOLVE Trial Data at Major…

Event summary

Eupraxia Pharmaceuticals will present three abstracts from its RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE) at ACG and UEG conferences in October 2026.
Poster presentations at ACG (Oct 12) and UEG (Oct 18) will highlight improvements in dysphagia symptoms and histopathological features of EoE.
Phase 2b portion of the RESOLVE trial, currently recruiting, expects interim data in December 2026.
Eupraxia's Diffusphere™ technology aims to optimize local, controlled drug delivery for EoE and other inflammatory gastrointestinal diseases.

The big picture

Eupraxia Pharmaceuticals is positioning itself as a leader in targeted drug delivery for inflammatory gastrointestinal diseases. The upcoming presentations at ACG and UEG conferences will provide critical insights into the efficacy and durability of its EP-104GI treatment for eosinophilic esophagitis. The company's proprietary Diffusphere™ technology could transform drug delivery, potentially reducing adverse events and improving patient outcomes. The market for EoE treatments is growing rapidly, with over 450,000 affected individuals in the United States alone, presenting a significant opportunity for Eupraxia.

What we're watching

Clinical Efficacy: Whether the RESOLVE trial data will demonstrate sustained efficacy of EP-104GI in treating EoE symptoms and histopathological features.
Regulatory Pathway: The pace at which Eupraxia can advance EP-104GI through Phase 2b and potential regulatory approval.
Market Opportunity: How Eupraxia's Diffusphere™ technology could expand into other therapeutic areas beyond gastrointestinal diseases.